Wednesday, July 16, 2025 7/16/2025

Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease

Award Number: R43DK137624
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2025

Group Awards By:

View Award Description

Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease - PROJECT SUMMARY Diabetic kidney disease (DKD) is a major complication associated with Type 1 and Type 2 diabetes. Approximately 25% of patients with diabetes develop DKD. DKD is the leading cause of kidney failure and accounts for 44% of all end-stage renal disease cases. It is associated with heart disease and heart failure, stroke, and early death. Treatment options for DKD are limited and focus on slowing progression to end-stage renal disease through glycemic control. Current FDA-approved treatments do not address pathogenic mechanisms driving the disease. The pathophysiology of DKD is related to prolonged exposure to high blood sugar, leading to non-specific glycation of proteins and subsequent formation of toxic advanced glycation end-products (AGEs). Evidence suggests that accumulation of AGEs in the kidneys plays a role in the vascular complications associated with diabetes, including DKD. Revel Pharmaceuticals is developing a novel class of therapeutics designed to cleave one of the most abundant AGEs accumulating in DKD, carboxymethyl-lysine (CML), thus removing a significant driver of DKD. Using rational design approaches, we have engineered enzymes that cleave free CML and CML modified peptides. Our goal in this Phase I grant is to optimize lead drug candidates and demonstrate enzyme activity on physiologically relevant DKD substrates. Our specific aims are to (1) engineer CML oxidase to efficiently cleave CML modifications from physiological substrates (2) characterize CML oxidase activity on model proteins & human tissues. Successful completion of this Phase I SBIR project will yield the first therapeutic enzyme designed to remove and repair AGE damage in vivo. In Phase II, we will carry out in vivo efficacy and IND-enabling studies with our collaborators at the National Mouse Metabolic Phenotyping Center to support an IND submission.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	REVEL PHARMACEUTICALS INC.	2325 3RD ST STE 214	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	12/4/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $324,015 )
2024	2024	REVEL PHARMACEUTICALS INC.	2325 3RD ST STE 214	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	4/29/2024	NEW	$324,015
														Subtotal = $324,015

Grand Total All Awards = $324,015

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease

Award Number: R43DK137624

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer